MoonLake Immunotherapeutics (NASDAQ: MLTX) climbed approximately 6% in premarket trading after reporting highly encouraging 52-week results from its pivotal Phase 3 VELA-1 and VELA-2 studies evaluating sonelokimab (SLK) in patients with moderate-to-severe hidradenitis suppurativa (HS). The long-term data reinforced investor confidence that the company may be developing a best-in-class treatment in a disease area with significant unmet medical needs.

The standout result was the durability and magnitude of patient responses after one year of treatment. MoonLake Immunotherapeutics (NASDAQ: MLTX) reported that 67.2% of patients achieved HiSCR75, a key measure indicating a 75% reduction in inflammatory lesions. The outcome compares favorably with historical performance reported by currently available therapies, strengthening the competitive positioning of sonelokimab.

Even more notably, 33.1% of patients achieved HiSCR100, representing complete clinical clearance of inflammatory lesions. Additionally, 26.0% reached IHS4-100, indicating complete inflammatory remission. The therapy also delivered meaningful reductions in pain and improvements in patient quality of life, outcomes that are particularly important in a chronic and debilitating condition such as hidradenitis suppurativa.

The positive data further validate MoonLake’s proprietary Nanobody platform and reinforce the growing investment thesis around sonelokimab. Hidradenitis suppurativa remains a challenging inflammatory skin disease with limited treatment options, creating a sizable commercial opportunity for therapies capable of delivering superior efficacy and long-term disease control.

Investors were also encouraged by the company’s advancing regulatory timeline. Following successful Phase 3 VELA-TEEN results in adolescent patients and productive pre-BLA discussions with regulators, MoonLake Immunotherapeutics (NASDAQ: MLTX) plans to submit its Biologics License Application (BLA) by late September 2026. Management also intends to seek Priority Review, which could potentially accelerate the regulatory review process and bring the therapy to market sooner.

The latest results arrive at an important stage for the company. While biotechnology investors often focus on initial trial readouts, long-term durability data are frequently viewed as a critical determinant of commercial success, particularly in chronic inflammatory diseases where sustained efficacy is essential.

The 6% premarket gain reflects growing optimism that sonelokimab could emerge as a leading therapy in the hidradenitis suppurativa market. As MoonLake Immunotherapeutics (NASDAQ: MLTX) moves toward regulatory submission, investors will be closely monitoring the BLA filing, regulatory feedback, and potential commercialization plans. If approved, sonelokimab could become a significant growth driver and establish the company as a major player in immunology-focused therapeutics.